Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

The Efficacy and Safety of Iparomlimab and Tuvonralimab (QL1706) Combined With Lenvatinib as Neoadjuvant Therapy in Renal Cancer With Partial Nephrectomy Indications But High Surgical Risk：A Single Arm, Phase II Clinical Study

Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0) who have indications for kidney preservation surgery but have difficulty in preserving the kidney (R.E.N.A.L. score >= 10).

Study Overview

• Status: Recruiting
• Conditions: Clear Cell Renal Cell Carcinoma; Neoadjuvant Therapy; Iparomlimab and Tuvonralimab
• Intervention / Treatment: Drug: QL1706 Combined With Lenvatinib

• Study Type: Interventional
• Enrollment (Estimated): 25
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Zhiling Zhang, M.D; Phone Number: +862087342318; Email: zhangzhl@sysucc.org.cn
• Study Contact Backup: Name: Yulu Peng, M.D; Phone Number: +862087342318; Email: pengyl1@sysucc.org.cn

Study Locations

• China
  • Guangzhou, China, 0755
    • Recruiting
    • Sun Yat-sen University Cancer Center
    • Contact: Zhiling Zhang, M.D; Phone Number: +862087342318; Email: zhangzhl@sysucc.org.cn
    • Contact: Yulu Peng, M.D; Phone Number: +862087342318; Email: pengyl1@sysucc.org.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Voluntarily sign a written informed consent form (ICF).
2. Age at the time of enrollment is >= 18 and under 80 years old, with no gender restrictions.
3. The physical fitness score of the Eastern Cooperative Oncology Group (ECOG) in the United States is 0 or 1;
4. Expected survival period >= 3 months.
5. Preoperative biopsy pathology confirmed renal clear cell carcinoma or renal cell carcinoma mainly composed of clear cell carcinoma;
6. ECOG score 0 or 1;
7. The patient is willing to undergo kidney preservation surgery;
8. Indications for kidney preservation surgery are available, but limited renal cancer with high difficulty of kidney preservation surgery (stage T1N0M0 or T2N0M0, must meet R.E.N.A.L. score >= 10);
9. At least one measurable lesion (according to mRECIST v1.1 standard) that is suitable for repeated and accurate measurements.
10. Good organ function, screening laboratory test results meet the following criteria: (1) Hematology (no blood components or cell growth factors are allowed to support treatment within 2 weeks before starting treatment): a. Absolute neutrophil count (ANC) >= 1.5 × 10^9/L (1500/mm^3); b. Platelet count (PLT) >= 100 × 10^9/L (100000/mm^3); c. Hemoglobin (HB) >= 90 g/L; (2) Liver: a. Serum total bilirubin (TBIL) <= 1.5 × ULN; b. Alanine transaminase (ALT) and aspartate transaminase (AST) <= 2.5 × ULN; For subjects with liver metastases, AST and ALT are <= 5 × ULN, while serum albumin (ALB) is >= 28g/L. Coagulation function: international normalized ratio (INR) and activated partial thromboplastin time (APTT) are <= 1.5 × ULN;
11. The subjects are willing and able to comply with the scheduled visits, treatment plans, laboratory tests, and other requirements of the study.

Exclusion Criteria:

1. lymph node metastasis;
2. The tumor surrounds the renal artery;
3. Renal vein cancer thrombus;
4. Diffuse tumor growth, with no clear boundary from normal renal parenchyma;
5. General poor condition, anesthesia assessment cannot tolerate general anesthesia surgery;
6. Have serious cardiovascular and cerebrovascular diseases, uncontrollable hypertension and diabetes;
7. Patients who have long-term use of immunosuppressants after organ transplantation;
8. Patients who are currently using immunosuppressive drugs;
9. Patients with clear infection or fever;
10. Patients with T-cell lymphoma and myeloma;
11. Patients who have concurrent malignant tumors, are currently undergoing treatment for other benign or malignant tumors, or have a history of other malignant tumors within the past six months;
12. Metastatic renal cell carcinoma.
13. Received Chinese herbal medicine or immunomodulatory drugs with anti-tumor indications within 14 days prior to the first use of the investigational drug;
14. Perform systematic treatment (including thymosin, interferon, interleukin, except for local use to control pleural effusion).
15. Suffering from active or potentially recurrent autoimmune diseases, except for vitiligo, hair loss, psoriasis, or eczema that do not require systemic treatment; Hypothyroidism caused by autoimmune thyroiditis only requires stable doses of hormone replacement therapy; Type I diabetes requiring only a stable dose of insulin replacement therapy.
16. Simultaneously enrolled in another clinical study, unless it is an observational, non interventional clinical study or a follow-up period of an interventional study.
17. Known history of mental illness, drug abuse, alcoholism, or drug use.
18. Pregnant or lactating women.
19. Any past or current illness, treatment, or laboratory test abnormalities may confuse the research results, affect the full participation of the subjects in the study, or participation in the study may not be in the best interests of the subjects.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Iparomlimab and Tuvonralimab (QL1706) combined with Lenvatinib as neoadjuvant therapy; Lenvatinib Treatment Lenvatinib (8mg [body weight < 60 kg] or 12 mg [body weight ≥ 60 kg]) orally once daily, with or without food. Intravenous Infusion of QL1706(Injection) Infuse QL1706 at a dose of 5mg/kg intravenously every three weeks, constituting one treatment cycle, a total of 2 or 4 cycles.

Drug: QL1706 Combined With Lenvatinib; Lenvatinib Treatment Lenvatinib (8mg [body weight < 60 kg] or 12 mg [body weight ≥ 60 kg]) orally once daily, with or without food. Intravenous Infusion of QL1706(Injection) Infuse QL1706 at a dose of 5mg/kg intravenously every three weeks, constituting one treatment cycle, a total of 2 or 4 cycles.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Decline rate of tumor R.E.N.A.L score	Evaluation at the end of Cycle 2 or 4 (each cycle is 21 days) of QL1706 treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ORR	Objective Response Rate (ORR) based on RECIST 1.1 criteria.	Evaluation at the end of Cycle 2 or 4 (each cycle is 21 days) of QL1706 treatment

Collaborators and Investigators

• Sponsor: Sun Yat-sen University

Study record dates

Study Major Dates

• Study Start (Actual): November 21, 2025
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2028

Study Registration Dates

• First Submitted: January 29, 2026
• First Submitted That Met QC Criteria: January 29, 2026
• First Posted (Actual): February 5, 2026

Study Record Updates

• Last Update Posted (Actual): February 5, 2026
• Last Update Submitted That Met QC Criteria: January 29, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Neoadjuvant therapy; Clear Cell Renal Cell Carcinoma; Iparomlimab and Tuvonralimab
• Additional Relevant MeSH Terms: Urogenital Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Urologic Neoplasms; Carcinoma; Kidney Neoplasms; Carcinoma, Renal Cell; lenvatinib
• Other Study ID Numbers: 2025-FXY-071

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No